Corcept Therapeutics Incorporated (CORT) Posts Positive Phase 2 BELLA Data

Corcept Therapeutics (CORT) reported positive Phase 2 BELLA trial results for Lifyorli with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer, showing a median PFS of 7.2 months and ORR of 59%. Median OS data was not yet available. The results support Lifyorli's potential in this indication, according to the company.

Original reporting
Published Oct 26, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 12:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Corcept Therapeutics Incorporated (CORT) Posts Positive Phase 2 BELLA Data — source image
Decision brief

The 30-second read

$CORTBullishMed
01

Why it matters

The Phase 2 results provide a tangible catalyst that could influence short‑term price action and longer‑term valuation.

02

Market read

Positive early‑stage data are a material news event for a listed biotech, likely prompting trading activity.

03

What to watch

Future regulatory pathway and need for mature overall survival data could temper upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Corcept Therapeutics is expanding its oncology portfolio after earlier ROSELLA efforts, focusing on platinum‑resistant ovarian cancer.

Company-level read

Ticker impact

$CORTBullishHigh confidence
Context

Corcept Therapeutics reported positive Phase 2 BELLA trial results for Lifyorli in platinum‑resistant ovarian cancer.

Expected impact

likely upward pressure as the market prices in the encouraging efficacy signals.

Evidence & confidence

Phase 2 data with a 59% ORR and 7.2‑month median PFS are strong for a biotech, prompting short‑term buying interest.

Market effects

May boost sentiment in the ovarian‑cancer biotech niche and related oncology pipelines.

Limited to U.S. biotech investors; no broader regional effect.

Minor global impact, confined to specialty pharma sector.

Counterpoint

Data are early‑stage; efficacy may not translate to later trials, so caution is warranted.

Key entities

  • Corcept Therapeutics Incorporated

    Biopharma developing cortisol‑modulating therapies.

  • Lifyorli

    Investigational therapy combined with nab‑paclitaxel and bevacizumab.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.